Related Experiment Video
Updated: Jun 17, 2026

Detection of Polyfunctional T Cells in Children Vaccinated with Japanese Encephalitis Vaccine via the Flow Cytometry Technique
Published on: September 23, 2022
Immunological persistence in 4-6 and 7-9 year olds previously vaccinated in infancy with hexavalent DTPa-HBV-IPV/Hib
Michael Zinke1, Johann Disselhoff,
1Tengstedter Landstr, Hamburg, Germany.
Insights
The hexavalent DTPa-HBV-IPV/Hib vaccine provides long-lasting immunity against most childhood diseases up to age 9. However, pertussis immunity wanes, supporting the need for a booster dose in young children.
Area of Science:
- Pediatric Vaccinology
- Immunology
- Public Health
Background:
- The DTPa-HBV-IPV/Hib vaccine is the sole licensed hexavalent option for infant immunization.
- It offers simultaneous protection against six critical childhood diseases.
Purpose of the Study:
- To assess the persistence of immune response after four doses of the hexavalent vaccine.
- To evaluate antibody levels in children aged 4-6 and 7-9 years.
Main Methods:
- Serological follow-up of 403 children vaccinated with DTPa-HBV-IPV/Hib.
- Analysis of antibody persistence at ages 4-6 and 7-9 years post-vaccination.
Main Results:
- High seroprotective antibody levels persisted for diphtheria, Hib, and poliovirus up to age 9.
- Antibody levels for Hepatitis B and tetanus remained protective in a majority of subjects.
- Anti-pertussis toxin antibodies were detectable in less than 40% of subjects by age 9.
Conclusions:
- The DTPa-HBV-IPV/Hib vaccine induces durable immunity against most antigens.
- Declining pertussis immunity highlights the importance of booster doses for sustained protection.
Background:
The combined diphtheria-tetanus-pertussis-hepatitis B-inactivated poliomyelitis-Haemophilus influenzae conjugate vaccine (DTP a-HBV-IPV/Hib, Infanrix Hexa() GlaxoSmithKline Biologicals, Rixensart, Belgium) is the only hexavalent vaccine currently licensed for primary and booster vaccination of infants and provides simultaneous protection against six major diseases of childhood. The persistence of the immune response in children aged 4-6 and 7-9 years of age previously vaccinated with four doses of DTP a-HBV-IPV/Hib vaccine was assessed (www.clinicaltrials.gov.au 106744 NCT00356564 and 106745 NCT00335881).
Methods:
A blood sample was collected from 403 children, all of whom had received 3-dose primary vaccination and a booster dose in the second year of life with DTP a-HBV-IPV/Hib, in previous clinical vaccine trials in Germany.
Results:
Mean time from the fourth DTP a-HBV-IPV/Hib dose until serological follow-up ranged between 3.6 and 6.4 years. After the 4th DTP a-HBV-IPV/Hib dose, in subjects who had not received additional booster doses, seroprotective antibody levels persisted up to 9 years of age in >/=90% of subjects for diphtheria, Hib and poliomyelitis, in 77.2% subjects for Hepatitis B and in 64.7% of subjects for tetanus. Anti-pertussis toxin antibodies remained detectable in no more than 38.2% of subjects.
Conclusion:
With the exception of PT , the combined DTP a-HBV-IPV/Hib induces long lasting immune response against all vaccine antigens. Falling seropositivity against PT over time supports the recommended administration of a pertussis booster dose in 5-6 year old children in Germany.
Related Concept Videos
Immunological Memory
What is Immunological Memory?
Immunological memory is an integral function of the immune system that allows it to recognize and react more rapidly and effectively to pathogens previously encountered. This feature is...
Vaccinations
Vaccines
Development of Immunocompetence
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Poliomyelitis
Cells of the Adaptive Immune Response
